VNVC signed a strategic cooperation with Takeda, whose Dengue vaccine is licensed in over 30 countries, bringing vaccine solutions closer to the people.
According to experts, Dengue fever is progressing complexly in Vietnam. Since early 2023, the country has recorded over 87,000 cases and nearly 25 deaths.
Currently, Dengue has no specific treatment beyond symptom relief and no prevention vaccine. Transmission control is difficult due to limited public awareness, unstable prevention resources, and hard-to-monitor populated areas.
In this context, on Sept 28, VNVC signed an MoU with Takeda Pharmaceuticals (Asia Pacific), part of the Takeda Group (Japan).
At the ceremony, both sides agreed on training and scientific research to promote awareness and enhance medical staff expertise on Dengue prevention, including the vaccine.
Participating in the signing, Dr. Nguyen Ngo Quang from the Ministry of Health highly valued the Takeda-VNVC partnership. "We hope Vietnamese people can access the Dengue vaccine as soon as possible," he said.
Assoc. Prof. Dr. Tran Dac Phu, former Director of Preventive Medicine, shared his experience with Dengue outbreaks and deaths, understanding the vaccine's vital role in infectious disease prevention.
Mr. Phu praised VNVC's superior vaccination model and expressed joy at its growth and quality, with over 130 centers nationwide improving access to new global vaccines.
"I hope today's signing between VNVC and Takeda brings success and we can soon bring the Dengue vaccine to Vietnam, provided it meets efficacy and safety standards," Mr. Phu expected.
Mr. Ngo Chi Dung, VNVC Chairman and CEO, shared that desde its inception, VNVC's mission has been to provide the most complete range of high-quality vaccines equivalent to developed countries for Vietnamese people.
With strategic storage experience and global partnerships, VNVC is ready to work with manufacturers to bring vaccines for Dengue, Shingles, Hand-Foot-Mouth, and new-generation Hepatitis B to Vietnam.
The partnership opens prospects for advanced Dengue prevention methods, especially via vaccine, in Vietnam's future - Mr. Dung emphasized.
Takeda Vietnam's Chief Representative Katharina Geppert valued the VNVC partnership in bringing Takeda's high-quality prevention and health solutions closer to the Vietnamese public.
"At Takeda, we value the power of partnership with local health entities to address public health challenges together, including Dengue solutions," Katharina Geppert shared.
Takeda's vaccine (QDENGA) is licensed in over 30 countries including the EU, UK, Argentina, and nations with similar epidemiology like Indonesia, Brazil, and Thailand. It is not yet licensed in Vietnam.
D.KHOA
